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COMMENTARY
Down Syndrome and Leukemia: New Insights Into the
Epidemiology, Pathogenesis, and Treatment
INTRODUCTION
Down syndrome is the most common autosomal
chromosomal disorder with incidence ranging from 1 in
700 to 1:1,000 live births [1]. The protean manifestation
are mental retardation, congenital heart disease, and risk
for early death. The predominant cause of death is related
to the congenital heart defects followed by hypothy-
roidism, respiratory infections, and malignancy (particu-
larly, leukemia) [2,3]. Death from leukemia in Down
syndrome children is predominately in the younger ages
[2]. Down syndrome children account for approximately
3% of children with acute lymphoblastic leukemia (ALL)
and 5–8% of children with acute myeloid leukemia
(AML) diagnosed in the United States. Despite the fact
that the association of increased risk for leukemia with
Down syndrome have now been recognized for nearly
50 years, it is this relatively low frequency of the total
number of cases and the reluctance to give aggressive
chemotherapy in a developmentally challenged youngster
hindered the systematic evaluation of the pathogenesis and
treatment of leukemia in children with Down syndrome.
Within the last two decades, several important develop-
ments in the understanding of the biology and treatment of
leukemias in Down syndrome children have occurred.
These developments in general define the pivotal role
played by chromosome 21, both in childhood ALL and
AML. The serendipitous discovery of the unique drug
sensitivity of AML in Down syndrome [4] provided
additional impetus for these studies. What emerges is a
fascinating story for increased risk for leukemia on the one
hand and the increased sensitivity to chemotherapy on the
other [5]. In this issue of the journal, six articles describe
some of these developments and provide new insights on
the biology and treatment of leukemia in Down syndrome
[3,6–10]. It is a privilege to write this overview. The
articles will be reviewed in the context of epidemiology,
pathogenesis, and treatment/drug sensitivity. Some of the
remaining challenges will be identified in the summation.
Epidemiology of Leukemia in Children
With Down Syndrome
Ross et al. [3] describe the current status of the
epidemiology of leukemia in Down syndrome. First and
foremost, there is a 20-fold increased risk of leukemia in
individuals with Down syndrome [11,12]. Brewster and
Cannon [13] get credited with the first descriptions of
the association between Down syndrome and leukemia
in 1930. A striking feature of the increased risk for
malignancies is that there is an increased risk for leukemia
but not for other solid tumors with the exception of
testicular cancer, germ cell tumors, and retinoblastoma
[14,15]. The increased risk for leukemia appears to be for
the most part to a particularly high risk for one type of
AML, megakaryocytic leukemia (AMKL, M7 AML) [16].
The Children’s Oncology Group additionally show an
almost fourfold higher incidence of AML to ALL in Down
syndrome children [3]. It is fascinating that while the age
adjusted incidence of ALL similar to that seen in non-
Down syndrome children, the incidence of AML is highly
skewed towards the younger age with very few cases if any
beyond the age of 5 years confirming the observations
from population based registry of Down syndrome
children from Nordic countries [14,17].
Comments. Ross et al. [3] offer several suggestions
for further investigation of the increased risk for leukemia
in Down syndrome. They correctly point out that as of
now, the only potentially shared risk factor for both Down
syndrome and childhood leukemia is advanced maternal
age. Other avenues of study would include quantitation of
the exposure to radiation from the diagnostic X-ray studies
in Down syndrome for study of heart disease and studies
for investigation of intercurrent infections. Ross et al. [3]
focus on the relationship of infections in early infancy and
the risk for ALL. The infection hypothesis of Greaves et al.
[18,19] suggests that exposure to common infections in
early childhood may protect a child against ALL by
contributing to normal maturation of the immune system,
whereas children whose exposure is delayed will be at
comparatively higher risk. Greaves et al. suggest that these
may be the basis for the lower incidence of childhood
ALL in non-industrialized countries versus industrialized
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countries. Children with Down syndrome present a
paradox in this regard. On the one hand, the immune
deficiency that occurs in Down syndrome may predispose
to an increased risk of developing leukemia analogous to
the known increased risk of lymphoid malignancies in
children with other immune deficiencies. On the other
hand, while the age peak for children with Down synd-
rome and ALL appears to follow the age peak for
childhood ALL, the incidence of hyperdiploid ALL and
for that matter, ALL with t(12;21) is extremely low or non-
existent in Down syndrome children [8,20,21]. It has been
suggested that the increased incidence of childhood ALL
in the industrialized countries is largely due to the hyper-
diploid ALL. Recent studies from India suggest that the
incidence of TEL-AML t(12;21) is lower in the Indian
children with ALL [22]. It should also be noted that
hyperdiploid ALL is also less common in US black
children Smith et al. [23]. Thus, it appears that Down
syndrome is protective against the occurrence of hyperdi-
ploid ALL and ALL with t(12;21). This parallels the
pattern of ALL in less industrialized (and over crowded,
under-nutrition) societies. If so, what may be the basis for
this? Could there be a linkage with the relative folate
deficiency in Down syndrome and the low incidence of
hyperdiploid ALL? An intriguing parallel is the pattern of
incidence of leukemia and solid tumors in individuals
with homozygosity for C677T variant of methylene
tetrahydrofolate reductase, a folate pathway enzyme.
Recent studies have shown that homozygosity for C677T
MTHFR is protective against hyperdiploid ALL [24] and
these individuals are also at a low risk for colon cancer,
a cancer not found in Down syndrome children in the
population based studies from Denmark [14]. Thus it
would, indeed, be great interest to study the folate status
of children with Down syndrome, the US blacks (sub-
Saharan Africans), and the South Asians (Indian sub
continent) patient populations and to correlate with the
incidence of hyperdiploid ALL, and ALL with t(12;21) in
these populations.
Pathogenesis of Transient Leukemia/AML
and GATA1 Mutations
Massey [6] reviews the current knowledge of transient
leukemia in newborns with Down syndrome and Crispino
[7] provides an overview of the relationship of the recently
discovered GATA1 mutations and TL/AML in Down
syndrome children.
One of the more fascinating manifestations of Down
syndrome is the disorder variously known as transient
myeloproliferative disorder (TMD or transient leukemia),
first described by Schunk and Lehman in 1954 [25].
This disorder is typically seen in newborns associated
with a high incidence of spontaneous remissions [26].
The disease is largely clinically silent and frequently
discovered by routine blood counts done for other reasons
but in some cases the disease is life threatening. In severe
cases the infant may be born with hydrops fetalis and show
evidence of liver or multi-organ system failure. Retro-
spective reviews of suggest that neonatal mortality may
range from 11 to 55% (the higher figure includes stillborn
patients) [27,28]. In the POG 9481 prospective study 8 of
47 patients (17%) experienced early death [29]. And of
those who achieve spontaneous remission up to 30%
will subsequently develop AMKL [27,28,30]. Megakar-
yoblastic nature of the neonatal TMD/TL has been clearly
established by the electron microscopic studies of
Zipursky et al. [31] and as well by the more recent studies
using the platelet glycoprotein IIb/IIIA markers CD41/61.
Mutations of exon 2 of theGATA1 gene are universal [32].
Comments. Three important questions remain to be
answered. (1) What is the mechanism of the spontaneous
resolution of TMD/TL in the majority of the cases?
(2) Why do some infants develop hydrops fetalis and liver
dysfunction and die? (3) What is the mechanism for the
subsequent development of AMKL in up to 30% of the
infants with TMD/TL and can this be prevented? All three
appear to be linked. The most important new development
in the understanding of the biology of AML of Down
syndrome is the identification of the truncating mutations
involving the hematopoietic transcription factor gene
GATA1 (reviewed by Crispino [7]). GATA1 is located on
chromosome X and encodes for a zinc finger transcription
factor that is essential for normal erythroid and mega-
karyocytic differentiation. Mutations in exon 2 of GATA1
have been detected almost exclusively in trisomy 21
associated TMD/TL and in Down syndrome patients with
AMKL but not in non-Down syndrome AMKL cases [33].
The mutations result in the introduction of a premature
stop codon leading to the exclusive production of a smaller
GATA1 isoform named GATA1s measuring 40 kDa
compared to the normal full length 50 kDa isoform of
GATA1. Remarkably these 40 kDa isoform retains both
the zinc fingers that are involved in the DNA binding and
the interaction site with an essential cofactor named,
friend of GATA1 (FOG 1) [7]. It is interesting that all of
the GATA1 alterations reported to date abolished the
expression of the full length form but retain the expression
of GATA1s. This finding is of critical importance with
regard to the pathogenesis of AML. For example, mice
that totally lack GATA1 (knockout) die in embryogenesis
due to deficiencies in both primitive and definitive
erythropoiesis, while mice that express low levels of
GATA1 (knockdown) with varying degrees of anemia
and thrombocytopenia [34]. In these knockdown mice,
the GATA1 deficient megakaryocytes are defective in
terminal maturation and exhibit abnormal proliferation
when expanded in vitro [35]. In parallel to this, it is of
interest that blast cells from Down syndrome children with
AMKL and TMD/TL express CD36 [36], in contrast to the
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low or lack of expression of CD36 in non-Down syndrome
AMKL. Further, the expression of wild type GATA1 in the
MGS cell line (derived from a Down syndrome child with
AMKL) have been shown to partially rescue differentia-
tion [37]. It is to be noted that an earlier study suggested
that low GATA1 expression may be a marker for good
response in AML [38].
Based on the above and additional observations in
aborted Down syndrome fetuses, twins with Down
syndrome and prospective studies of screening for GATA1
mutations at birth, Crispino suggests an origin of TMD/TL
fetal liver, which would explain both the spontaneous
resolution of TMD/TL and the occurrence and the fatal
form of TMD and TL with liver failure [7,39]. Crispino
speculates that GATA1 mutations occur in fetal liver
hematopoietic progenitors in both Down syndrome and
unaffected individuals but that the mutations have a
selective advantage only against the backdrop of trisomy
21, because of the increased gene dosage effort of key
transcription cofactors AML1 and ETS2 which are
localized to chromosome 21 [39]. Spontaneous resolution
then reflects the transition from fetal liver erythropoiesis to
marrow derived postnatal erythropoiesis. The hepatic
dysfunction and hydrops fetalis in some of the cases are
due to a high TMD burden in the liver resulting in hepatic
fibrosis from excessive PDGF and TGF production [6,40].
The later emergence of true AMKL then is due to persis-
tence of these clones or occurrence of the same GATA1
mutation simultaneously in the fetal and marrow derived
hematopoietic precursors. This hypothesis supported by
the finding of GATA1 mutations in asymptomatic infants
with Down syndrome, demonstration of the same GATA1
mutation both at the initial TMD as well as the latter
AMKL [41].
The question of whether the children presenting with
severe manifestations of TMD/TL should be treated
pharmacologically with chemotherapeutic agents remains
unanswered at present. Anecdotal data from Toronto
shows that low dose cytosine arabinoside (Ara-C) regimen
might induce lasting ‘‘remissions’’ in these children and
low dose Ara-C regimen has also been shown to be
effective in the treatment of myelodysplastic syndrome
seen in later infancy in the Down syndrome children [42].
Unpublished data from POG 9481 study also suggests that
Down syndrome infants with TMD/TL treated with the
low dose Ara-C and who survived have not developed
AMKL (G Massey, personal communication). This raises
the intriguing possibility that low dose Ara-C,(1–2
courses) may even prevent later occurrence of AMKL.
In any case, the treatment of children with hydrops or
severe liver dysfunction remains problematic. First, many
of these children have far advanced hepatic failure with
some autopsy have virtually no viable hepatocytes
(unpublished personal observation). In others, there may
severe lung disease from either hyperviscosity or pul-
monary fibrosis. It is of note that several CCG studies have
identified pulmonary toxicity as a feature of the toxicity
profile in Down syndrome and leukemia. The unique risk
for pulmonary toxicity has not been fully explained
although it is of interest that an existing hypothesis for the
site of production of platelets suggests that megakaryo-
cytes home in to the lung and then release platelets by
explosion [43].
Treatment of ALL and Down Syndrome
Basal et al. [8] review the experience of Down
syndrome children treated between 1952 study for NIH
consensus standard risk ALL (age 1 and 10; initial
WBC 50 103/ml). Fifty-nine of 2,174 registered
patients or 3% had Down syndrome. The study confirmed
the prior observations that hyperdiploid ALL and ALL
with TEL/AML1 do not occur in Down syndrome
(reviewed by Lange [20]). At the same time, adverse
translocations or hypodiploidy was also not observed in
the ALL Down syndrome cohort. Prior reviews had
suggested that the outcome in Down syndrome children
with ALL is either the same or somewhat inferior to
ALL in non-Down syndrome, thus contrasting with the
markedly superior outcome of AML in Down syndrome
versus non-Down syndrome children. In narrowing down
into one single study and as well, restricting the analysis to
NIH consensus standard risk group, Basal et al. [8] were
able to isolate some of the issues. First, among the B
lineage ALL patients, as a whole, the ALL Down
syndrome cohort had a lower 4 year EFS of compared to
the non-Down syndrome ALL cohort but this difference
was no longer significant when the groups were adjusted
for the presence of either TEL-AML1 or triple trisomies
(hyperdiploidy) (78.6% vs. 82.3%, P¼ 0.14). With regard
to overall survival, however, non-Down syndrome
cohort did better compared to the Down syndrome group.
The authors suggested that the contributing factors for the
difference in the low overall survival for Down syndrome
ALL cohort might be the increased infection rate or less
intensive salvage therapy offered for Down syndrome
children with relapse. For example, in their study, only 8%
of Down syndrome patients relapsed or received a bone
marrow transplant compared to 29% of the non-Down
syndrome cohort with relapse. Some other differences
emerged in this study. No case of T lineage leukemia was
observed in this study in Down syndrome children
compared to an incidence of 5.9% in the non-Down
syndrome cohort on CCG 1952. The well-known metho-
trexate related toxicity was confirmed. Down syndrome
children spent longer in the hospital than non-Down
syndrome cohort, and there was a higher incidence of
hyperglycemia. There was also a higher incidence of
bacteremia in the Down syndrome cohort. Interestingly,
the infection risk was far greater during remission in the
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post remission phases of the treatment in Down syndrome
patients possibly reflecting increased risk of bacteremia
resulting from the increased incidence of mucositis. This
increased risk of infections, however, did not seem to
translate in toxic deaths although Basal et al. [8] do not
provide actual numbers toxic deaths for either group.
Comments: The EFS data in Down syndrome ALL
are somewhat consistent with the known in vitro drug
sensitivity studies, which also did not show a specific
difference between the Down syndrome and non-Down
syndrome groups in terms of drug sensitivity [44]. These
in vitro drug sensitivity data should be treated with some
degree of caution. MTT assay was successful in only 45%
of the Down syndrome ALL cohort whereas typically
investigators found up to 80% of BP ALL samples the test
is successful for at least for one drug. In 6 of the 20 tested
cases of Down syndrome-ALL, the cell count was too low
on Day 4, indicating a high spontaneous apoptosis rate in
control wells. Zwaan et al. [44] also did not correct for
cytogenetic subgroups (hyperdiploidy or TEL-AML1)
between the Down syndrome ALL and the non-Down
syndrome ALL cohorts. Further, Basal et al. [8] while
presenting an exhaustive summary of the comparison of
results between Down syndrome and non-Down syndrome
cohorts treated on CCG 1952 did not provide data on the
actual relapse rate and the number of withdrawals for
toxicity between the two groups nor the actual numbers of
deaths during remission.
In any case, current data at best show equivalent results
between Down syndrome and non-Down syndrome
cohorts in contrast to the markedly superior results in the
Down syndrome AML patients compared to non-Down
syndrome AML. Potential reasons are: (1) the results are
already at a high level for both groups and thus differences
may not be easy to appreciate, (2) oxygen radical mediated
drug induced apoptosis may be much more evident with
high dose chemotherapy as is frequently done in AML
compared to the relatively low dose therapy in ALL, (3)
Ara-C is not a frequently used drug in the therapy of
standard risk ALL, (4) dose adjustments of methotrexate
on account of concern for mucositis may actually result in
under dosing of Down syndrome ALL patients, and (5)
finally as pointed out by Basal et al. [8] relapsed Down
syndrome ALL patients may be under treated because of
parental and physician concerns.
Drug Sensitivity of AML in Down Syndrome
Taub and Ge [10] provide concise review of the series
of drug sensitivity studies done by the Wayne State
University group, particularly in relation to the unique and
endogenous modulation of Ara-C metabolism in Down
syndrome. Taub and Ge also provide the initial evidence
for the potential linkage of GATA1 mutation and the
increased sensitivity to Ara-C. To summarize briefly,
the altered folate metabolism in Down syndrome children
on account of the increased activity of cystathionineb
synthase (CBS), results in low levels of endogenous dCTP
low s-adenosyl methionine. Low endogenous dCTP
results in release of the feedback inhibition deoxycytidine
cytidine kinase, the enzyme that phosphorylates both
deoxycytidine and Ara-C resulting in a ‘‘favorable’’ Ara-
CTP to dCTP ratio. In addition, Taub et al. have shown that
expression levels of the Ara-C degrading enzyme, cytidine
deaminase (CDA; gene localized to chromosome 1p), are
lower in Down syndrome leukemic cells compared to non-
Down syndrome cases, an additional factor contributing to
the increased Ara-CTP generation in Down syndrome
megakaryoblasts [45]. More recent experiments of Taub
et al. provide evidence that increased CDA expression
could be linked to decreased co-cooperativity between
the mutated GATA1 and a short form promoter of CDA.
Stable transfection of the wild type GATA1 coding cDNA
into the Down syndrome AMKL cell line, CMK (which
contains mutated GATA1 gene), resulted in increased
Ara-C resistance and a threefold lower level of Ara-CTP
generation. Consistent with this hypothesis are data from
pharmacologic interventions aimed at reducing endogen-
ous dCTP by either prior treatment with methotrexate [46]
and hydroxyurea [47] or fludarabine [48] (inhibitors of
ribonucleotide reductase), which enhance Ara-C cyto-
toxicity.
Comments: While clear evidence exists with regard
to this unique modulation of Ara-C sensitivity in Down
syndrome, less obvious is the generalized increased
sensitivity of Down syndrome AML to anthracyclines
and as well, other drugs [44,49,50]. A possible reason
appears to be the well-known increased generation of
oxygen radicals in Down syndrome observed and the well-
documented increased spontaneous apoptosis in multiple
cell systems including neuronal cells (reviewed by
Ravindranath [5] and Taub and Ge [10] in this issue). A
modest increase in superoxide dismutase as occurs in
Down syndrome in the absence of a concomitant increase
in glutathione peroxidase and catalase might result in
increased hydroxyl radical formation which itself might
be quite toxic. Studies from the Wayne State group provide
additional insight to the increased production of reactive
oxygen species (ROS) in Down syndrome cells. Chien
et al. [51] demonstrate that an increased mitochondrial
production and leakage of superoxide in the CMK cell line
compared to non-Down syndrome AMKL cell lines MEG-
O1 (derived from a Philadelphia chromosome positive
CML case in blast crisis) and HL60 erythroleukemia cell
line (also derived from a Philadelphia chromosome
positive CML patient). The increased to superoxide
production correlates with the increased drug sensitivity
of CMK versus MEG-O1 versus HL60. In these studies
there was no significant increase in hydroxyl radical
production in the CMK cell line, presumably related to an
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increase in catalase activity. These preliminary data in cell
lines suggest that the primary reason for the increased
spontaneous apoptosis in Down syndrome is the increased
superoxide generation from mitochondrial respiratory
activity and that the modest increases in superoxide
dismutase and catalase are not sufficient to detoxify all of
the ROS generated. Other evidence suggests that ETS2
over-expression in transgenic mice and in Down syndrome
predisposes apoptosis via the p53 pathway [52]. ETS2 is
also induced by oxidative stress and sensitizes cells to
hydrogen peroxide induced apoptosis [53]. Together,
these studies suggest that increased ROS production on
the background of increased ETS2 expression and
imbalance of the antioxidant enzymes SOD1/GPXþ
catalase such as occurs in Down syndrome may prime
the cells for spontaneous apoptosis and thereby drug
induced apoptosis. The studies by Chien et al. suggest
that the increased ROS itself is likely from increased
mitochondrial respiratory activity possibly linked to the
increased gene dosage effect of NADH dehydrogenase
ubiquinone flavoprotein 3 (NDUFV3) gene, a 10KDA
component of complex 1 localized to chromo-
some21q22.3 [51].
Treatment of AML in Down Syndrome
This topic is covered within two articles in this issue.
The article by Gamis [9] is factual, historical, and
comprehensive. It is clear that the unique responsiveness
of AML in Down syndrome became obvious only after the
general usage of high dose Ara-C in the treatment
regimens for AML. In the POG 8498 study all children
with Down syndrome and AML entered on study survived
event free [4]. Subsequent reports (reviewed by Gamis [9]
in this issue) confirmed the superior outcome in AML
children with Down syndrome with EFS of 75–80%. With
the exception of one study, all used high dose Ara-C post
remission. However, given the some what increased
toxicity in children with Down syndrome with current
AML regimens, some reduction in intensity of treatment
seems appropriate. In light of the markedly increased
sensitivity in vitro to Ara-C an obvious question is can we
reduce toxicity by lowering the cytarabine dose from 3 to
1 g/m2 in each of the high dose cytarabine courses. The
answer is likely yes but needs to be explored in prospective
studies to assure that the current high cure rates are not
jeopardized. Further future studies would have to recog-
nize that some of the AML cases in children (particularly
older children) with Down syndrome may represent the
true de novo AML cases and not linked to GATA1
mutations. The response in such cases may be same as
can expected from the cytogenetic abnormalities other
than constitutional trisomy 21. Absence of the classic
AMKL features and low or lack of expression of the
megakaryocyte maturation marker CD36 (thrombospon-
din receptor) may provide a clue [36,54] and in such cases
studies of GATA1 mutations may be necessary.
SUMMARY
The discovery of the unique sensitivity of Down
syndrome-AML to chemotherapy, the observation of the
linkage of reduced function associated GATA1 mutations
with Down syndrome-AMKL/TMD have provided a great
impetus to understand the mechanistic basis of the patho-
genesis of Down syndrome-AML and as well the sensi-
tivity to chemotherapy. The recent studies have proved
critical in determining the relationship of folate pathway
to cytarabine sensitivity as well the pivotal role of increas-
ed ROS in determining cellular sensitivity to chemo-
therapeutic agents. Several questions that are specific to
Down syndrome and leukemia remain to be elucidated.
Nevertheless, it is clear that Down syndrome is a unique
paradigm for increased risk for leukemogenesis on the one
hand, drug sensitivity on the other. Down syndrome may
yet become the prototype disorder defining the integral
relationship of life (cell proliferation) and death (sponta-
neous apoptosis).
ACKNOWLEDGMENT
Dr. Ravindranath is supported by Georgie Ginopolis
Endowment, and holds the Georgie Ginopolis Chair for




for Pediatric Cancer and Hematology
Wayne State University School of Medicine
Children’s Hospital of Michigan
Detroit, Michigan
REFERENCES
1. Down syndrome prevalence at birth—United States, 1983–1990.
MMWR 1994;43:617–622.
2. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with
Down’s syndrome in the USA from 1983 to 1997: A population-
based study. Lancet 2002;359:1019–1025.
3. Ross A, Spector LG, Robison LL, Olshan AF. Epidemiology of
leukemia in children with Down syndrome. Pediatr Blood Cancer
2005;44:8–12.
4. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid
leukemia (AML) in Down’s syndrome is highly responsive to
chemotherapy: Experience on Pediatric Oncology Group AML
Study 8498. Blood 1992;80:2210–2214.
5. Ravindranath Y. Down syndrome and acute myeloid leukemia: The
paradox of increased risk for leukemia and heightened sensitivity to
chemotherapy. J Clin Oncol 2003;21:3385–3387.
6. Massey GV. Transient leukemia in newborns with Down syndrome.
Pediatr Blood Cancer 2005;44:29–32.
7. Crispino JD. GATA1 mutations in Down syndrome. Pediatr Blood
Cancer 2005;44:40–44.
Down Syndrome and Leukemia 5
8. Basal M. Lymphoblast biology and outcome among children with
Down syndrome and ALL treated on CCG-1952. Pediatr Blood
Cancer 2005;44:21–28.
9. Gamis A. Acute myeloid leukemia and Down syndrome: Evolution
of modern therapy—State of the art review. Pediatr Blood Cancer
2005;44:13–20.
10. Taub JW, Ge Y. Down syndrome, drug metabolism and chromo-
some 21. Pediatr Blood Cancer 2005;44:33–39.
11. Krivit W, Good RA. Simultaneous occurrence of mongolism and
leukemia: Report of a nation wide survey. Am J Dis Child 1957;94:
289–293.
12. Robison LL. Down syndrome and leukemia. Leukemia 1992;6:
5–7.
13. Brewster HFCH. Acute lymphatic leukemia: Report of a case in
eleven month Mongolian Idiot. New Orleans Med Surg J 1930;82:
872–873.
14. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and
solid tumours in individuals with Down’s syndrome. Lancet 2000;
355:165–169.
15. Satge D, Sommelet D, Geneix A, et al. A tumor profile in Down
syndrome. Am J Med Genet 1998;78:207–216.
16. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and
Down’s syndrome: A review. Pediatr Hematol Oncol 1987;4:211–
230.
17. Rajantie J, Siimes MA. Long-term prognosis of children with
Down’s syndrome and leukaemia: A 34-year nation-wide experi-
ence. J Intellect Dis Res 2003;47:617–621.
18. Greaves MF, Wiemels J. Origins of chromosome translocations in
childhood leukaemia. Nat Rev Cancer 2003;3:639–649.
19. Greaves MF. Biological models for leukaemia and lymphoma.
IARC Sci Publ 2004;157:351–372.
20. Lange B. The management of neoplastic disorders of haematopoi-
esis in children with Down’s syndrome. Br J Haematol 2000;110:
512–524.
21. Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical charac-
teristics and treatment outcome of children with acute lymphocytic
leukemia and Down’s syndrome. A Pediatric Oncology Group
study. Cancer 1991;67:1057–1063.
22. Sazawal S, Bhatia K, Gutierrez MI, et al. Paucity of TEL-AML 1
translocation, by multiplex RT-PCR, in B-lineage acute lympho-
blastic leukemia (ALL) in Indian patients. Am J Hematol 2004;76:
80–82.
23. Smith MA, Chen T, Simon R. Age-specific incidence of acute
lymphoblastic leukemia in US children: In utero initiation model.
J Natl Cancer Inst 1997;89:1542–1544.
24. Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydro-
folate reductase (MTHFR) polymorphisms and risk of molecularly
defined subtypes of childhood acute leukemia. Proc Natl Acad Sci
USA 2001;98:4004–4009.
25. Schunk GJLW. Mongolism and congenital leukemia. JAMA 1954;
155:250–251.
26. Weinstein HJ. Congenital leukaemia and the neonatal myelo-
proliferative disorders associated with Down’s syndrome. Clin
Haematol 1978;7:147–154.
27. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelo-
poiesis of infancy associated with trisomy 21. Am J Pediatr
Hematol Oncol 1993;15:392–399.
28. Isaacs H, Jr. Fetal and neonatal leukemia. J Pediatr Hematol Oncol
2003;25:348–361.
29. Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment
of potentially lethal diseases in transient leukemia of Down
syndrome: Pediatric Oncology Group Study. J Pediatr Hematol
Oncol 2002;24:9–13.
30. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: A
review. Pediatr Hematol Oncol 1992;9:139–149.
31. Zipursky A, Christensen H, De Harven E. Ultrastructural studies
of the megakaryoblastic leukemias of Down syndrome. Leuk
Lymphoma 1995;18:341–347.
32. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mech-
anisms of myeloid leukemogenesis in Down syndrome. Blood
2004;103:399–406.
33. Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of
GATA1 is an initiating event in Down syndrome leukemogenesis.
Blood 2003;101:4298–4300.
34. McDevitt MA, Shivdasani RA, Fujiwara Y, et al. A ‘‘knockdown’’
mutation created by cis-element gene targeting reveals the
dependence of erythroid cell maturation on the level of transcrip-
tion factor GATA-1. Proc Natl Acad Sci USA 1997;94:6781–6785.
35. Vyas P, Ault K, Jackson CW, et al. Consequences of GATA-1 defi-
ciency in megakaryocytes and platelets. Blood 1999;93:2867–2875.
36. Savasan SBS, Ravindranath Y. CD36 expression is associated
with superior in vitro Ara-C sensitivity in acute megakaryocytic
leukemia with and without Down syndrome. Med Pediatr Oncol
2003;41:274–275, abs#O070.
37. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the
GATA-1 gene in the transient myeloproliferative disorder of Down
syndrome. Blood 2003;102:2960–2968.
38. Shimamoto T, Ohyashiki K, Ohyashiki JH, et al. The expression
pattern of erythrocyte/megakaryocyte-related transcription factors
GATA-1 and the stem cell leukemia gene correlates with hemato-
poietic differentiation and is associated with outcome of acute
myeloid leukemia. Blood 1995;86:3173–3180.
39. Taub JW, Mundschau G, Ge Y, et al. Prenatal origin of GATA1
mutations may be an initiating step in the development of mega-
karyocytic leukemia in Down syndrome. Blood 2004;104:1588–
1589.
40. Terui T, Niitsu Y, Mahara K, et al. The production of transforming
growth factor-beta in acute megakaryoblastic leukemia and its
possible implications in myelofibrosis. Blood 1990;75:1540–
1548.
41. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient
leukemia and acute megakaryoblastic leukemia of Down syn-
drome. Blood 2003;101:4301–4304.
42. Tchernia G, Lejeune F, Boccara JF, et al. Erythroblastic and/or
megakaryoblastic leukemia in Down syndrome: Treatmentwith low-
dose arabinosyl cytosine. J Pediatr Hematol Oncol 1996;18: 59–62.
43. Zucker-Franklin D, Philipp CS. Platelet production in the pulmo-
nary capillary bed: New ultrastructural evidence for an old concept.
Am J Pathol 2000;157:69–74.
44. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity
profiles of acute myeloid and lymphoblastic leukemia and normal
peripheral blood mononuclear cells in children with and without
Down syndrome. Blood 2002;99:245–251.
45. Ge Y, Jensen TL, Stout ML, et al. The role of cytidine deaminase
and GATA1 mutations in the increased cytosine arabinoside sensi-
tivity of Down syndrome myeloblasts and leukemia cell lines.
Cancer Res 2004;64:728–735.
46. Newman EM, Villacorte DG, Testi AM, et al. Biochemical interac-
tions between methotrexate and 1-beta-D-arabinofuranosylcyto-
sine in hematopoietic cells of children: A Pediatric Oncology
Group study. Cancer Chemother Pharmacol 1990;27:60–66.
47. Bhalla K, Swerdlow P, Grant S. Effects of thymidine and hydro-
xyurea on the metabolism and cytotoxicity of 1-beta-D arabinofur-
anosylcytosine in highly resistant human leukemia cells. Blood
1991;78:2937–2944.
48. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates
metabolism of cytarabine in patients with acute myelogenous
leukemia during therapy. J Clin Oncol 1993;11:116–124.
49. Taub JW, Stout ML, Buck SA, et al. Myeloblasts from Down
syndrome children with acute myeloid leukemia have increased
6 Ravindranath
in vitro sensitivity to cytosine arabinoside and daunorubicin.
Leukemia 1997;11:1594–1595.
50. Frost BM, Gustafsson G, Larsson R, et al. Cellular cytotoxic drug
sensitivity in children with acute leukemia and Down’s syndrome:
An explanation to differences in clinical outcome? Leukemia 2000;
14:943–944.
51. Chien MB, S, Johnson RM, Stout M. Increased generation of reac-
tive oxygen species correlates with cytotoxicty in acute myeloid
leukemia (AML) of Down syndrome and is augmented by cyto-
toxic agents affecting the mitochondrial electron transport chain.
AACR. Orlando; 2004:ABS#3098.
52. Wolvetang EJ, Wilson TJ, Sanij E, et al. ETS2 overexpression in
transgenic models and in Down syndrome predisposes to apoptosis
via the p53 pathway. Hum Mol Genet 2003;12:247–255.
53. Sanij E, Hatzistavrou T, Hertzog P, et al. Ets-2 is induced by
oxidative stress and sensitizes cells to H(2)O(2)-induced apopto-
sis: Implications for Down’s syndrome. Biochem Biophys Res
Commun 2001;287:1003–1008.
54. Karandikar NJ, Aquino DB, McKenna RW, et al. Transient
myeloproliferative disorder and acute myeloid leukemia in Down
syndrome. An immunophenotypic analysis. Am J Clin Pathol 2001;
116:204–210.
Down Syndrome and Leukemia 7
